Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy (FreeDNA-CAV)

Majadahonda Iron Gate University

Status: Completed

Conditions: Cardiac Allograft Vasculopathy

Treatments: Diagnostic Test: Donor-derived Cell Free DNA

Study type: Observational

Funder types: Other

Identifiers

NCT04791852

FreeDNA-CAV

Details and patient eligibility

About

Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography > 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.

Enrollment: 94 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients over 18 and under 80 years old, HT > 1 year ago

Exclusion criteria

• Patients under 18 or over 80 years old
• Multiorgan transplant
• History of acute cellular rejection ≥ 1R or antibody mediated rejection in the previous 6 months
• Concomitant infection by CMV